But this is not the case with ordinary bidding procurement, and the difference between them is quite obvious.
1, the area of drug bidding has changed from decentralized to centralized, which saves a lot of manpower and material resources for pharmaceutical companies and drug management companies, and is a low-cost choice; As far as medical institutions are concerned, the benefits of price increase in medical institutions continue, and doctors' clinical expenses (that is, kickbacks) will still be guaranteed, and they have no objection; For patients, the price reduction is expected to be greater than the previous tender, so I have great expectations for this tender.
2. The initiative of drug bidding is transferred from drug management company to pharmaceutical factory.
3. The choice of first-and second-line distributors by pharmaceutical companies weakens the strong position of the terminal network.
4. The probability of winning the bid for drugs is greatly improved, and the competition is more intense. The probability of winning the bid for drugs has increased from three in the past to many, which means that the sales will be more intense and cruel than before. In order to ensure that the product wins the bid, the price will inevitably go down further.